XL-281

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameXL-281
Drug Alias NameBMS-908662XL-281
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitorsB-raf V600E inhibitors
TargetsC-Raf kinaseSerine/threonine-protein kinase B-rafB-raf V600E
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsThyroid Cancer, Papillary +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyExelixis Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsThyroid Cancer, Papillary +[5] 

Other Information

ATC CodeN/A
Related LinksN/A